Prothena (NASDAQ: PRTA) revenue plunges in 2025 but guides lower 2026 cash burn
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Prothena Corporation plc reported significantly weaker 2025 financial results while highlighting progress across its partnered neurology pipeline. For 2025, the company posted a net loss of $244.1 million, nearly double the prior year’s $122.3 million, as revenue fell to $9.7 million from $135.2 million driven by lower collaboration payments.
Research and development expenses declined to $134.9 million and general and administrative expenses to $59.4 million, reflecting lower clinical, personnel, manufacturing, and consulting costs, though results included $30.1 million of restructuring charges and a $43.2 million non-cash tax expense. Prothena ended 2025 with $308.4 million in cash, cash equivalents and restricted cash and no debt, and had about 53.8 million ordinary shares outstanding as of February 12, 2026.
For 2026, Prothena expects net cash used in operating and investing activities of $50–$55 million and to finish the year with roughly $255 million in cash at the midpoint, excluding up to $105 million of potential clinical milestone receipts from partners. The company also secured shareholder and court approval to create distributable reserves, allowing its board to consider a share redemption program in 2026 at its discretion, and noted multiple late-stage trials with Roche, Novo Nordisk, and Bristol Myers Squibb targeting Parkinson’s, ATTR amyloidosis, and Alzheimer’s disease.
Positive
- Strong liquidity and moderated cash burn: Prothena ended 2025 with $308.4 million in cash, cash equivalents and restricted cash and no debt, and guides 2026 net cash use to $50–$55 million with an expected year-end cash balance of about $255 million.
- Advanced partnered pipeline and milestone potential: Multiple Phase 3 and Phase 2 programs with Roche, Novo Nordisk, and Bristol Myers Squibb are progressing, with potential to earn up to $105 million in clinical milestones by end of 2026 and approximately $3 billion in longer-term aggregate milestones.
- Capital return flexibility: Shareholders and the Irish High Court approved a reduction in share capital to create distributable reserves, enabling the board to consider a 2026 share redemption program through open market purchases or other permissible means, subject to financial condition and board discretion.
Negative
- Severe revenue decline and larger losses: Total revenue fell to $9.7 million in 2025 from $135.2 million in 2024 as collaboration payments decreased, while net loss nearly doubled to $244.1 million, including $30.1 million of restructuring charges and a $43.2 million non-cash tax expense.
- Reduced asset base and higher restructuring overhang: Total assets shrank to $326.8 million from $547.1 million year over year, and Prothena booked a $13.3 million restructuring liability at year-end 2025 following discontinuation of the birtamimab program and workforce reductions.
Insights
Revenue collapsed as milestone income faded, but cash runway and late-stage partnerships remain substantial.
Prothena’s 2025 results show a sharp reset after a milestone-heavy 2024. Total revenue dropped to
Operating discipline is evident: R&D fell to
Strategically, the story hinges on partnered programs: Phase 3 trials of prasinezumab and coramitug are underway with primary completions expected in
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________
FORM 8-K
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2026
_______________________________________________________
(Exact name of registrant as specified in its charter)
_______________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
| (Address of principal executive offices, including Zip Code) | ||||||||||||||||||||
Registrant’s telephone number, including area code: 011-353 -1 -236-2500
___________________________________________________
(Former Name or Former Address, if Changed Since Last Report.)
___________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. | ||||
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically incorporate by reference the information furnished pursuant to Item 2.02 (including Exhibit 99.1) of this Current Report.
On February 19, 2026, Prothena Corporation plc issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of that press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits | ||||
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press Release dated February 19, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | February 19, 2026 | PROTHENA CORPORATION PLC | ||||||||||||
| By: | /s/ Tran B. Nguyen | |||||||||||||
| Name: | Tran B. Nguyen | |||||||||||||
| Title: | Chief Financial Officer and Chief Strategy Officer | |||||||||||||
Exhibit 99.1
PRESS RELEASE
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
•Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million
•Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026
•Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029
•Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029
•Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease
•Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways
•At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate
•Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
DUBLIN, Ireland, February 19, 2026-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2025. In addition, the Company provided business highlights and 2026 financial guidance.
“In 2025, our partner Roche initiated the Phase 3 PARAISO clinical trial evaluating prasinezumab in early Parkinson’s disease and Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy, both with primary completions expected in 2029. In addition, we expect our partner Bristol Myers Squibb to decide on the potential advancement of PRX019 in 2026 and to complete the ongoing Phase 2 TargetTau-1 clinical trial evaluating BMS-986446
in early Alzheimer’s in 1H 2027. These partnered programs have the potential to earn up to approximately $3 billion in future aggregate milestones in addition to potential future royalties,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. “We also unveiled our proprietary CYTOPE® technology with presentations at scientific congresses highlighting preclinical data from our TDP-43 CYTOPE® program. In addition, we are evaluating PRX012-TfR, our once-monthly, subcutaneous anti-Aβ antibody combined with transferrin receptor technology for the treatment of Alzheimer’s in preclinical studies. We expect to share more data from our preclinical programs later this year.”
2025 Business Highlights and Upcoming Milestones
Updates on Active Clinical Development Portfolio
Prasinezumab, a potential first-in-class antibody for the treatment of Parkinson’s disease that is designed to target a key epitope within the C-terminus of alpha-synuclein and is the focus of a worldwide collaboration with Roche.
•Roche is evaluating prasinezumab in the ongoing Phase 3 PARAISO clinical trial in ~900 participants with early-stage Parkinson's disease; primary completion expected in 2029 (NCT07174310)
•Roche has stated that prasinezumab has peak sales potential greater than $3.5 billion (unadjusted) and could be the first disease-modifying treatment for a condition that affects 10 million people worldwide
Coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) designed to deplete the pathogenic, non-native forms of the transthyretin (TTR) protein, is being developed by Novo Nordisk as part of its up to $1.2 billion acquisition of Prothena’s ATTR amyloidosis business and pipeline.
•Novo Nordisk is evaluating coramitug in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participants with ATTR-CM; primary completion expected in 2029 (NCT07207811)
•Novo Nordisk presented Phase 2 results during a late-breaking session at the American Heart Association Scientific Sessions on November 10, 2025
•Potential to earn a clinical milestone in 1H 2026 when prespecified enrollment criteria are met in ongoing Phase 3 clinical trial by Novo Nordisk
BMS-986446 (formerly PRX005), a potential best-in-class antibody for the treatment of Alzheimer’s disease that specifically targets a key epitope within the microtubule binding region (MTBR) of tau, a protein implicated in the causal pathophysiology of Alzheimer’s disease.
•Bristol Myers Squibb is conducting the Phase 2 TargetTau-1 clinical trial in approximately 310 patients with early Alzheimer’s disease; primary completion expected in 1H 2027 (NCT06268886)
•Bristol Myers Squibb conducted a Phase 1 open-label single-dose clinical trial to assess a subcutaneous administration (NCT06955741)
•BMS-986446 granted Fast Track designation by U.S. FDA as a treatment for Alzheimer’s disease
PRX019, a potential treatment of neurodegenerative diseases in development in collaboration with Bristol Myers Squibb.
•Bristol Myers Squibb obtained the exclusive global license for PRX019 in 2024
•Prothena is conducting a Phase 1 first-in-human clinical trial to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of single ascending and multiple doses in healthy adults with completion expected in 2026
•Potential to earn a clinical milestone by end of 2026 should Bristol Myers Squibb decide to further develop PRX019
Updates on Active Preclinical Development Portfolio
TDP-43 CYTOPE, a proprietary preclinical program enabling precision intracellular targeting of TDP-43 pathology, a defining pathogenic feature of ALS and other TDP-43 proteinopathies. TDP-43 CYTOPE preclinical data demonstrates the potential of Prothena’s CYTOPE technology to target intracellular disease pathways.
•Prothena presented a poster at Neuroscience 2025 (Society for Neuroscience) and the International Symposium of ALS/MND demonstrating the potential of TDP-43 CYTOPE in multiple preclinical models
PRX012-TfR, a preclinical program combining PRX012, our wholly-owned, single-injection, once-monthly antibody delivered subcutaneously with transferrin receptor technology to potentially improve its product profile.
•Phase 1 ASCENT clinical program preliminary results demonstrated that patients on the 400 mg dose level of PRX012 for 18 months reached a mean centiloid (CL) level of ~16.0 CL and 9 of 12 achieved amyloid negativity (defined as <24.1 CL). However, the robust plaque clearance was associated with non-competitive rates of ARIA-E.
•Based on the totality of the results, Prothena is developing PRX012-TfR (transferrin receptor) in preclinical studies while exploring potential partnership opportunities
Upcoming Investor Conference
Members of the senior management team will present and participate in investor meetings at the following upcoming investor conference:
•The Citizens Life Sciences Conference on Wednesday, March 11, 2026; fireside chat at 10:10 a.m. ET in Miami, FL
Fourth Quarter and Full Year of 2025 Financial Results
For the fourth quarter and full year of 2025, Prothena reported net loss of $21.6 million and $244.1 million, respectively, as compared to a net loss of $58.0 million and $122.3 million for the fourth quarter and full year of 2024, respectively. The full year of 2025 net loss includes $30.1 million of restructuring charges associated with the discontinuation of the birtamimab program and the reduction in workforce announced in June 2025, and a $43.2 million net non-cash income tax expense to book a full valuation allowance against its federal deferred tax assets. Net loss per share was $0.40 and $4.53 for the fourth quarter and full year of 2025, respectively, as compared to a net loss per share of $1.08 and $2.27 for the fourth quarter and full year of 2024, respectively.
Prothena reported total revenue of $21 thousand and $9.7 million for the fourth quarter and full year of 2025, respectively, as compared to total revenue of $2.1 million and $135.2 million for the fourth quarter and full year of 2024, respectively. Total revenue for the fourth quarter and full year of 2025 was primarily from collaboration revenue from Bristol Myers Squibb related to the partial performance of our PRX019 Phase 1 clinical trial obligation. Total revenue for the full year of 2024, was primarily from collaboration revenue from Bristol Myers Squibb, including revenue recognized from the execution of the PRX019 Global License Agreement by Bristol Myers Squibb, which included an $80 million upfront payment in 2024.
Research and development (R&D) expenses totaled $14.6 million and $134.9 million for the fourth quarter and full year of 2025, respectively, as compared to $50.2 million and $222.5 million for the fourth quarter and full year of 2024, respectively. The decrease in R&D expenses for the fourth quarter and full year of 2025 compared to the same periods in the prior year was primarily due to lower clinical trial expenses, lower personnel expenses, lower manufacturing and lower consulting expenses. R&D expenses
included non-cash share-based compensation expense of $2.1 million and $14.1 million for the fourth quarter and full year of 2025, respectively, as compared to $4.7 million and $20.9 million for the fourth quarter and full year of 2024, respectively.
General and administrative (G&A) expenses totaled $12.6 million and $59.4 million for the fourth quarter and full year of 2025, respectively, as compared to $16.8 million and $67.2 million for the fourth quarter and full year of 2024, respectively. The decrease in G&A expenses for the fourth quarter and full year of 2025 compared to the same periods in the prior year was primarily due to lower personnel expenses and lower consulting expenses. G&A expenses included non-cash share-based compensation expense of $5.0 million and $21.5 million for the fourth quarter and full year of 2025, respectively, as compared to $5.8 million and $25.0 million for the fourth quarter and full year of 2024, respectively.
Total non-cash share-based compensation expense was $7.1 million for the fourth quarter of 2025 and $37.6 million for the full year of 2025 which included $2.1 million in non-cash share-based compensation expense related to restructuring charges, as compared to $10.5 million and $46.0 million for the fourth quarter and full year of 2024, respectively.
As of December 31, 2025, Prothena had $308.4 million in cash, cash equivalents and restricted cash, and no debt.
As of February 12, 2026, Prothena had approximately 53.8 million ordinary shares outstanding.
2026 Financial Guidance
The Company expects its full year net cash used in operating and investing activities to be $50 to $55 million and to end the year with approximately $255 million (midpoint) in cash, cash equivalents, and restricted cash. The estimated full year 2026 net cash used from operating and investing activities is primarily driven by an estimated net loss of $67 to $72 million, which includes an estimated $24 million of non-cash share-based compensation expense. This financial guidance does not include the potential to earn up to $105 million of aggregate clinical milestone payments from strategic partners in 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb.
Share Redemption Program
Prothena convened an Extraordinary General Meeting of shareholders on November 19, 2025 at which shareholders voted to approve a reduction in Prothena’s share capital to create distributable reserves, which was subsequently confirmed by the Irish High Court. The creation of distributable reserves provides flexibility for the Board of Directors to potentially return capital to shareholders via a share redemption program through open market purchases or other permissible means in 2026. Any such program would be subject to the discretion of the Board of Directors and Prothena’s then-current financial condition.
Conference Call Details
Prothena management will discuss these results and its 2026 financial guidance during a live audio conference call today, Thursday, February 19, 2026, at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.
To access the call via dial-in, please dial +1 (800) 715-9871 (U.S. and Canada toll free) or +1 (646) 307-1963 (international) five minutes prior to the start time and refer to conference ID number 1706941.
A replay of the call will be available until February 26, 2026, via dial-in at +1 (800) 770-2030 (U.S. and Canada toll free) or +1 (609) 800-9909 (international), Conference ID Number 1706941.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund advancement of our pipeline and completion of our ongoing clinical trials; the continued advancement of our preclinical and clinical pipeline, including the potential and advancement of our CYTOPE technology and expected milestones in 2026, 2027, and beyond; the treatment potential, designs, proposed mechanisms of action, and potential administration of prasinezumab, coramitug, BMS-986446, PRX019, TDP-43 CYTOPE, and PRX012-TfR; plans for ongoing and future clinical trials of prasinezumab, coramitug, BMS-986446, and PRX019; the expected timing of reporting data from preclinical studies and clinical trials; projections regarding peak sales and patient population for prasinezumab; timing of and amounts we may receive under our collaborations with Novo Nordisk and Bristol Myers Squibb; our anticipated net cash burn from operating and investing activities for 2026 and expected cash balance at the end of 2026; our estimated net loss and non-cash share-based compensation expense for 2026; and the potential to return capital to shareholders via a share redemption program or other permissible means. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to uncertainties related to the completion of operational and financial closing procedures, audit adjustments and other developments that may arise that would require adjustments to the preliminary financial results included in this press release, as well as those described in the “Risk Factors” sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 6, 2025, discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC, and our Annual Report on Form 10-K to be filed with the SEC for our fiscal year 2025. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
PROTHENA CORPORATION PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited - amounts in thousands except per share data)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||
| Collaboration revenue | $ | 21 | $ | 2,123 | $ | 9,634 | $ | 135,107 | ||||||||||||||||||
| Revenue from license and intellectual property | — | — | 50 | 50 | ||||||||||||||||||||||
| Total revenue | 21 | 2,123 | 9,684 | 135,157 | ||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Research and development | 14,586 | 50,172 | 134,852 | 222,519 | ||||||||||||||||||||||
| General and administrative | 12,646 | 16,848 | 59,392 | 67,199 | ||||||||||||||||||||||
| Restructuring costs | (3,008) | — | 30,080 | — | ||||||||||||||||||||||
| Total operating expenses | 24,224 | 67,020 | 224,324 | 289,718 | ||||||||||||||||||||||
Loss from operations | (24,203) | (64,897) | (214,640) | (154,561) | ||||||||||||||||||||||
| Other income, net | 2,624 | 5,396 | 13,811 | 25,631 | ||||||||||||||||||||||
Loss before income taxes | (21,579) | (59,501) | (200,829) | (128,930) | ||||||||||||||||||||||
| Provision for (benefit from) income taxes | 10 | (1,545) | 43,263 | (6,620) | ||||||||||||||||||||||
Net loss | $ | (21,589) | $ | (57,956) | $ | (244,092) | $ | (122,310) | ||||||||||||||||||
Basic and diluted net loss per ordinary share | $ | (0.40) | $ | (1.08) | $ | (4.53) | $ | (2.27) | ||||||||||||||||||
Shares used to compute basic and diluted net loss per share | 53,831 | 53,815 | 53,829 | 53,772 | ||||||||||||||||||||||
PROTHENA CORPORATION PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited - amounts in thousands)
| December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Assets | |||||||||||
| Cash and cash equivalents | $ | 307,531 | $ | 471,388 | |||||||
| Prepaid expenses and other current assets | 7,662 | 14,024 | |||||||||
| Total current assets | 315,193 | 485,412 | |||||||||
| Property and equipment, net | 2,144 | 3,081 | |||||||||
| Operating lease right-of-use assets | 8,125 | 10,708 | |||||||||
| Restricted cash, non-current | 860 | 860 | |||||||||
| Other non-current assets | 482 | 47,047 | |||||||||
| Total non-current assets | 11,611 | 61,696 | |||||||||
| Total assets | $ | 326,804 | $ | 547,108 | |||||||
| Liabilities and Shareholders’ Equity | |||||||||||
| Accrued research and development | $ | 4,329 | $ | 13,428 | |||||||
Deferred revenue, current | 2,664 | 8,850 | |||||||||
Restructuring liability | 13,303 | — | |||||||||
| Lease liability, current | 2,886 | 2,610 | |||||||||
| Other current liabilities | 17,661 | 23,613 | |||||||||
| Total current liabilities | 40,843 | 48,501 | |||||||||
Deferred revenue, non-current | — | 3,448 | |||||||||
| Lease liability, non-current | 5,487 | 8,233 | |||||||||
Total non-current liabilities | 5,487 | 11,681 | |||||||||
| Total liabilities | 46,330 | 60,182 | |||||||||
| Total shareholders’ equity | 280,474 | 486,926 | |||||||||
| Total liabilities and shareholders’ equity | $ | 326,804 | $ | 547,108 | |||||||
Contacts:
Mark Johnson, CFA, Vice President, Investor Relations
650-837-8550, IR@prothena.com
Media@prothena.com
FAQ
How did Prothena (PRTA) perform financially in full year 2025?
Prothena reported a net loss of $244.1 million in 2025, compared with $122.3 million in 2024. Total revenue dropped to $9.7 million from $135.2 million, mainly due to lower collaboration revenue after a large upfront payment recognized in 2024.
What is Prothena’s 2026 cash burn guidance and expected year-end cash?
Prothena expects full year 2026 net cash used in operating and investing activities of $50–$55 million and projects ending 2026 with approximately $255 million in cash, cash equivalents, and restricted cash at the midpoint, excluding potential receipt of up to $105 million in clinical milestones.
What was Prothena’s cash position and debt level at December 31, 2025?
As of December 31, 2025, Prothena held $308.4 million in cash, cash equivalents and restricted cash and reported no debt. This liquidity supports ongoing R&D programs and provides runway ahead of key clinical milestones and potential capital returns in 2026.
Which late-stage clinical programs are highlighted in Prothena’s update?
Key programs include Roche’s Phase 3 PARAISO trial of prasinezumab in early Parkinson’s disease and Novo Nordisk’s Phase 3 CLEOPATTRA trial of coramitug in ATTR-CM, both with primary completion expected in 2029, plus Bristol Myers Squibb’s Phase 2 TargetTau-1 trial of BMS-986446 in early Alzheimer’s disease.
Does Prothena plan any share repurchases or redemptions in 2026?
Prothena obtained shareholder and Irish High Court approval to reduce share capital and create distributable reserves, allowing flexibility for a potential 2026 share redemption program through open market purchases or other means, subject to board discretion and the company’s then-current financial condition.
What restructuring and tax items affected Prothena’s 2025 results?
The 2025 net loss includes $30.1 million of restructuring charges tied to discontinuing the birtamimab program and workforce reductions, and a $43.2 million net non-cash income tax expense to establish a full valuation allowance against federal deferred tax assets, both materially impacting reported earnings.
Filing Exhibits & Attachments
4 documents
Prothena